AIM
IOVA icon

Aigen Investment Management’s Iovance Biotherapeutics IOVA Stock Holding History

Aigen Investment Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-18,510
Closed -$274K – 898
2024
Q1 		$274K Buy
+18,510
New +$215K 0.06% 465
2022
Q1 		– Sell
-17,996
Closed -$333K – 805
2021
Q4 		$333K Buy
+17,996
New +$396K 0.02% 756
2020
Q3 		– Sell
-10,608
Closed -$291K – 979
2020
Q2 		$291K Buy
+10,608
New +$349K 0.04% 621

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Aigen Investment Management's IOVA Position: Q2 2024 in Review

Aigen Investment Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2024, closing a stake of 18,510 shares — an estimated $274K sold.

Aigen Investment Management first reported a position in IOVA in Q2 2020 and held it in 3 quarters. The position peaked at $333K in Q4 2021. 295 funds tracked by Wall St. Rank hold IOVA as of Q2 2024.

  • Aigen Investment Management reported no remaining Iovance Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Aigen Investment Management sold 18,510 Iovance Biotherapeutics shares in Q2 2024, an estimated $274K.
  • Aigen Investment Management first reported a position in Iovance Biotherapeutics in Q2 2020 and held it in 3 quarters.
  • Aigen Investment Management's Iovance Biotherapeutics position peaked at $333K in Q4 2021.
  • 295 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2024.

Based on Aigen Investment Management's 13F filing for Q2 2024, filed 9 Aug 2024.